NuScale Power Stock Has 195% Upside, According to This Wall Street Analyst

NuScale Power shares are down ~40% since early 2026, but analyst George Gianarikas (Canaccord Genuity) forecasts ~195% upside from the current price, with three additional analysts calling for at least 100% potential over 12 months. The bullish case centers on NuScale’s planned 6-gigawatt SMR partnership with ENTRA1 and TVA for the eastern U.S. coast, plus Romanian regulatory approval for a separate SMR project. The article also flags valuation sensitivity to an aggressive 5% terminal growth rate, implying higher uncertainty around the upside estimates.

Analysis

This is still a long-duration equity story disguised as a near-term catalyst. When valuation depends on aggressive terminal assumptions, the stock is effectively a real-options trade on future project conversion, and that makes it extremely sensitive to discount rates, execution delays, and any hint of dilution. In other words, the upside case is less about current fundamentals and more about the market choosing to underwrite a far-dated commercialization path.

The more interesting second-order effect is that a successful flagship utility commitment would likely not just re-rate SMR; it would widen the gap between capital-light nuclear enablers and pure development-stage names. If one project advances, the safer beneficiaries are the picks-and-shovels suppliers and established nuclear services names, because they monetize buildout without taking the full financing and schedule risk. If the project stalls, the market will probably punish the entire "advanced nuclear" basket, but SMR should underperform the more diversified names by a wide margin.

The main contrarian point is that regulatory progress is not economic validation. The market may be extrapolating approval into a bankable cash-flow machine, while the real gating item is a funded, priced contract with credible economics; until then, every rally is vulnerable to being repriced by higher rates or a capital raise. Near-term price action can stay violent on analyst upgrades, but the 1-3 month catalyst path is weak unless management produces hard contracting evidence, and the 6-18 month risk is dilution if development spending outruns commercialization.

Key Decisions for Investors

• Do not chase SMR strength on the analyst note alone; treat it as a watchlist name until a binding power contract and financing terms are disclosed. Risk/reward is poor if the stock is already trading on terminal-value enthusiasm rather than visible cash flow.
• Pair trade: long BWXT, short SMR over the next 1-3 months. BWXT captures nuclear buildout/supply-chain demand with materially lower execution and dilution risk; SMR is the fragile leg if milestones slip.
• For investors already long SMR, hedge with 3-6 month downside puts into the next catalyst window. The thesis should be considered broken if there is no binding commercial agreement or if project timelines push out again.
• Alert item, not a recommendation: if management announces a credible PPA plus third-party financing, reconsider the entire sector stance. That is the event that would convert SMR from a story stock into a fundable project developer.